toby clark, it's good to have you on the programme. only have these drugs changed their own industry, they're changing other businesses, too. where are you seeing the greatest impact? it's still really early days at the moment. some of the stuff we're seeing coming through, first of all, is in the supplement sector. so obviously if people are taking in fewer calories, they want to make sure they're getting all the nutrients that they need. so in the us especially, we've seen a couple of brands that have launched supplements specifically for glp—1 users. we've also seen it in some of the us retail stores, where we've got one of the health food firms is creating special glp—1 drug areas in the store to help guide people through their requirements. it's already hitting multiple sectors. we're seeing it in cosmetics, where you're seeing more claims coming through about skin plumping, to try and counteract that ozempic face challenge. and nestle, for example, relatively recently launched a range of foods specifically designed for glp—1 user